SLRX vs VTR · $4.9M cap vs P/E 149, rev $1.73B
Salarius Pharmaceuticals Inc (SLRX) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Salarius Pharmaceuticals Inc (SLRX) is a biotechnology company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported SLRX revenue for 2023-03-31 was $0. Net income was -$5.3M. SLRX currently screens at market cap $4.9M.
Latest reported VTR revenue for 2026-06-30 was $1.73B. Net income was $72.2M. Revenue was up 4.4% from 2026-03-31 to 2026-06-30. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
SLRX currently screens at market cap $4.9M. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the SLRX and VTR stock pages for the full models.
Not investment advice.